{"NCT01587703":{"publications":["23604113","24875858","26220994","26976114","27070701","27509377","28484033"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","recruitment_status":"Completed","last_update_posted":"March 16, 2020"},"NCT01492673":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma","recruitment_status":"Completed","last_update_posted":"October 29, 2019"},"NCT00464620":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Trial of Dasatinib in Advanced Sarcomas","recruitment_status":"Completed","last_update_posted":"November 23, 2018"},"NCT01643278":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic","recruitment_status":"Completed","last_update_posted":"January 10, 2017"},"NCT02048371":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes","recruitment_status":"Recruiting","last_update_posted":"August 10, 2021"},"NCT01331135":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (Aflac ST0901)","recruitment_status":"Completed","last_update_posted":"May 29, 2020"},"NCT01353625":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.","recruitment_status":"Completed","last_update_posted":"May 6, 2021"},"NCT01518413":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors","recruitment_status":"Completed","last_update_posted":"February 27, 2015"},"NCT01956669":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","recruitment_status":"Completed","last_update_posted":"August 12, 2020"},"NCT01154816":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia","recruitment_status":"Completed","last_update_posted":"May 13, 2020"},"NCT02116777":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies","recruitment_status":"Completed","last_update_posted":"March 26, 2021"},"NCT01286987":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","recruitment_status":"Completed","last_update_posted":"January 10, 2019"},"NCT01583543":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma","recruitment_status":"Completed","last_update_posted":"May 19, 2017"},"NCT01858168":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma","recruitment_status":"Recruiting","last_update_posted":"November 27, 2020"},"NCT02044120":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma","recruitment_status":"Completed","last_update_posted":"January 12, 2021"},"NCT01154452":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma","recruitment_status":"Completed","last_update_posted":"August 15, 2018"},"NCT00743496":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma","recruitment_status":"Completed","last_update_posted":"August 17, 2017"},"NCT02107963":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors","recruitment_status":"Completed","last_update_posted":"August 17, 2021"},"NCT00445965":{"publications":["25869102"],"projects":["3R01CA180279-05S1"],"title":"Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"October 29, 2020"},"NCT01610570":{"publications":["25869102","31392992"],"projects":["3R01CA180279-05S1","3R01CA204915-02S1"],"title":"Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma","recruitment_status":"Terminated","last_update_posted":"March 2, 2018"},"NCT01684150":{"publications":["26118503","27070701","27535106","33371192"],"projects":["5R01CA176745-09"],"title":"A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving","recruitment_status":"Completed","last_update_posted":"August 4, 2016"},"NCT02141828":{"publications":["26118503","27070701","27082517","32414848"],"projects":["5R01CA176745-09","3R01CA204396-02S1","1U01CA232486-01"],"title":"A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene","recruitment_status":"Completed","last_update_posted":"May 8, 2020"},"NCT01987362":{"publications":["26220994","26976114","27070701","27509377","28484033","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies","recruitment_status":"Completed","last_update_posted":"January 5, 2018"},"NCT02259114":{"publications":["26220994","26976114","27070701","27509377","28484033","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","recruitment_status":"Completed","last_update_posted":"January 26, 2021"},"NCT01713582":{"publications":["26976114","27070701","30642575","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09","1U54CA224019-01"],"title":"A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)","recruitment_status":"Completed","last_update_posted":"January 26, 2021"},"NCT02296476":{"publications":["26976114","27070701","33371192"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09"],"title":"A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)","recruitment_status":"Terminated","last_update_posted":"January 26, 2021"},"NCT02158858":{"publications":["26976114","27070701","30642575"],"projects":["3R01CA124633-11A1S1","5R01CA176745-09","1U54CA224019-01"],"title":"A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis","recruitment_status":"Recruiting","last_update_posted":"August 25, 2021"},"NCT01897571":{"publications":["27070701","27082517"],"projects":["5R01CA176745-09","3R01CA204396-02S1"],"title":"Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT02082977":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma","recruitment_status":"Terminated","last_update_posted":"February 25, 2020"},"NCT02395601":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas","recruitment_status":"Completed","last_update_posted":"September 6, 2019"},"NCT01949883":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma","recruitment_status":"Completed","last_update_posted":"September 6, 2019"},"NCT02157636":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"June 7, 2018"},"NCT02303782":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)","recruitment_status":"Withdrawn","last_update_posted":"September 1, 2016"},"NCT02034123":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma","recruitment_status":"Terminated","last_update_posted":"December 6, 2019"},"NCT02177812":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)","recruitment_status":"Terminated","last_update_posted":"June 28, 2019"},"NCT02261779":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible (TCP-AML)","recruitment_status":"Unknown","last_update_posted":"July 7, 2015"},"NCT02273102":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA)","recruitment_status":"Completed","last_update_posted":"July 21, 2020"},"NCT01943851":{"publications":["27070701","30642575"],"projects":["5R01CA176745-09","1U54CA224019-01"],"title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies","recruitment_status":"Completed","last_update_posted":"May 19, 2021"},"NCT02601937":{"publications":["27070701"],"projects":["5R01CA176745-09"],"title":"A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 2, 2021"},"NCT02098538":{"publications":["27082517"],"projects":["3R01CA204396-02S1"],"title":"Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"April 27, 2021"},"NCT02267603":{"publications":["27093365","30651320","30726175","33879601"],"projects":["2UM1CA154967-07"],"title":"Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"March 22, 2021"},"NCT02431260":{"publications":["27509377","28484033","30642575"],"projects":["3R01CA124633-11A1S1","1U54CA224019-01"],"title":"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies","recruitment_status":"Terminated","last_update_posted":"June 14, 2019"},"NCT02307240":{"publications":["27509377"],"projects":["3R01CA124633-11A1S1"],"title":"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors","recruitment_status":"Completed","last_update_posted":"September 3, 2019"},"NCT02427451":{"publications":["28111464"],"projects":["3R01CA205967-03S2"],"title":"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"November 6, 2019"},"NCT02236195":{"publications":["28988769"],"projects":["3U24CA210999-02S1"],"title":"Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes","recruitment_status":"Completed","last_update_posted":"September 1, 2017"},"NCT02334527":{"publications":["28988769"],"projects":["3U24CA210999-02S1"],"title":"Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy","recruitment_status":"Terminated","last_update_posted":"November 16, 2018"},"NCT00831792":{"publications":["29017058"],"projects":["1U54CA224079-01"],"title":"TKI258 in Castrate Resistant Prostate Cancer","recruitment_status":"Completed","last_update_posted":"September 11, 2019"},"NCT00753688":{"publications":["29212731"],"projects":["3R01CA180279-05S1"],"title":"Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (PALETTE)","recruitment_status":"Completed","last_update_posted":"August 22, 2013"},"NCT01920191":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma","recruitment_status":"Completed","last_update_posted":"April 20, 2016"},"NCT02454634":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)","recruitment_status":"Completed","last_update_posted":"November 7, 2018"},"NCT02794883":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma","recruitment_status":"Unknown","last_update_posted":"April 5, 2019"},"NCT02017717":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT02337491":{"publications":["29421984","29508855"],"projects":["1U01CA224160-01","1U01CA224348-01"],"title":"Pembrolizumab +/- Bevacizumab for Recurrent GBM","recruitment_status":"Completed","last_update_posted":"December 22, 2020"},"NCT02311582":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT01952769":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma","recruitment_status":"Unknown","last_update_posted":"September 13, 2016"},"NCT02336165":{"publications":["29421984","29508855"],"projects":["1U01CA224160-01","1U01CA224348-01"],"title":"Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma","recruitment_status":"Completed","last_update_posted":"July 15, 2021"},"NCT02327078":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","recruitment_status":"Completed","last_update_posted":"August 28, 2020"},"NCT02313272":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas","recruitment_status":"Completed","last_update_posted":"August 10, 2021"},"NCT02335918":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors","recruitment_status":"Completed","last_update_posted":"December 9, 2019"},"NCT02337686":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Pembrolizumab in Treating Patients With Recurrent Glioblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"January 29, 2020"},"NCT02550249":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Neoadjuvant Nivolumab in Glioblastoma (Neo-nivo)","recruitment_status":"Completed","last_update_posted":"April 11, 2017"},"NCT02529072":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)","recruitment_status":"Completed","last_update_posted":"March 26, 2020"},"NCT02526017":{"publications":["29421984","29508855","30660727"],"projects":["1U01CA224160-01","1U01CA224348-01","1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)","recruitment_status":"Completed","last_update_posted":"July 31, 2020"},"NCT02617589":{"publications":["29421984","33976133"],"projects":["1U01CA224160-01","1U01CA224348-01","1U2CCA233262-01"],"title":"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)","recruitment_status":"Active, not recruiting","last_update_posted":"February 3, 2021"},"NCT02648633":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma","recruitment_status":"Terminated","last_update_posted":"May 31, 2017"},"NCT02658279":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype","recruitment_status":"Recruiting","last_update_posted":"July 22, 2021"},"NCT02658981":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Anti-LAG-3 Alone &amp; in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2021"},"NCT02667587":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)","recruitment_status":"Active, not recruiting","last_update_posted":"September 11, 2020"},"NCT02798406":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)","recruitment_status":"Completed","last_update_posted":"July 15, 2021"},"NCT02829723":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"July 27, 2021"},"NCT02852655":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma","recruitment_status":"Recruiting","last_update_posted":"October 1, 2020"},"NCT02937844":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme","recruitment_status":"Unknown","last_update_posted":"October 19, 2016"},"NCT02866747":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)","recruitment_status":"Recruiting","last_update_posted":"July 28, 2021"},"NCT02968940":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma","recruitment_status":"Completed","last_update_posted":"June 18, 2021"},"NCT00643097":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ACTIVATe)","recruitment_status":"Completed","last_update_posted":"February 1, 2017"},"NCT00458601":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)","recruitment_status":"Completed","last_update_posted":"January 16, 2018"},"NCT01480479":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)","recruitment_status":"Completed","last_update_posted":"January 16, 2018"},"NCT01498328":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)","recruitment_status":"Completed","last_update_posted":"February 17, 2020"},"NCT01130077":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas","recruitment_status":"Active, not recruiting","last_update_posted":"August 10, 2021"},"NCT02078648":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme","recruitment_status":"Completed","last_update_posted":"January 26, 2018"},"NCT02149225":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients","recruitment_status":"Completed","last_update_posted":"August 7, 2018"},"NCT02287428":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","recruitment_status":"Recruiting","last_update_posted":"May 21, 2021"},"NCT02193347":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)","recruitment_status":"Active, not recruiting","last_update_posted":"March 15, 2021"},"NCT00293423":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma","recruitment_status":"Completed","last_update_posted":"May 13, 2021"},"NCT01814813":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT02546102":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 13, 2018"},"NCT00045968":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Study of a Drug [DCVax&#174;-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)","recruitment_status":"Unknown","last_update_posted":"October 14, 2016"},"NCT00846456":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma","recruitment_status":"Completed","last_update_posted":"October 20, 2015"},"NCT02049489":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma","recruitment_status":"Completed","last_update_posted":"August 13, 2018"},"NCT00626483":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe)","recruitment_status":"Completed","last_update_posted":"March 9, 2021"},"NCT00639639":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ATTAC)","recruitment_status":"Active, not recruiting","last_update_posted":"January 26, 2021"},"NCT02366728":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"DC Migration Study for Newly-Diagnosed GBM (ELEVATE)","recruitment_status":"Active, not recruiting","last_update_posted":"November 7, 2019"},"NCT00345163":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) (BRAIN)","recruitment_status":"Completed","last_update_posted":"May 16, 2017"},"NCT00612430":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Ph II Bevacizumab + Etoposide for Pts w Recurrent MG","recruitment_status":"Completed","last_update_posted":"August 12, 2013"},"NCT00595322":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma","recruitment_status":"Completed","last_update_posted":"May 23, 2017"},"NCT01238237":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA","recruitment_status":"Completed","last_update_posted":"February 1, 2017"},"NCT01884740":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22","recruitment_status":"Recruiting","last_update_posted":"April 20, 2021"},"NCT00753246":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Nimotuzumab in Adults With Glioblastoma Multiforma","recruitment_status":"Completed","last_update_posted":"December 3, 2012"},"NCT02573324":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)","recruitment_status":"Active, not recruiting","last_update_posted":"May 24, 2021"},"NCT00730613":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma","recruitment_status":"Completed","last_update_posted":"October 9, 2017"},"NCT02209376":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma","recruitment_status":"Terminated","last_update_posted":"March 5, 2019"},"NCT01109095":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)","recruitment_status":"Completed","last_update_posted":"April 25, 2019"},"NCT01491893":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)","recruitment_status":"Active, not recruiting","last_update_posted":"January 12, 2021"},"NCT01301430":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)","recruitment_status":"Completed","last_update_posted":"December 4, 2015"},"NCT00390299":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme","recruitment_status":"Completed","last_update_posted":"January 2, 2020"},"NCT01174537":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma","recruitment_status":"Withdrawn","last_update_posted":"June 11, 2015"},"NCT01811992":{"publications":["29421984"],"projects":["1U01CA224160-01"],"title":"Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma","recruitment_status":"Completed","last_update_posted":"August 31, 2021"},"NCT01750918":{"publications":["29431697"],"projects":["1U54CA224068-01"],"title":"BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)","recruitment_status":"Completed","last_update_posted":"April 19, 2021"},"NCT01719380":{"publications":["29431697"],"projects":["1U54CA224068-01"],"title":"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer","recruitment_status":"Completed","last_update_posted":"June 23, 2021"},"NCT03098160":{"publications":["29485185"],"projects":["3R01CA187532-03S1"],"title":"Immunotherapy Study of Evofosfamide in Combination With Ipilimumab","recruitment_status":"Unknown","last_update_posted":"October 30, 2017"},"NCT00633724":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer","recruitment_status":"Completed","last_update_posted":"August 15, 2013"},"NCT00874588":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer","recruitment_status":"Completed","last_update_posted":"August 15, 2013"},"NCT02562755":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)","recruitment_status":"Completed","last_update_posted":"December 16, 2020"},"NCT02616185":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)","recruitment_status":"Completed","last_update_posted":"March 9, 2021"},"NCT01218867":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer","recruitment_status":"Terminated","last_update_posted":"December 10, 2019"},"NCT02857920":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors","recruitment_status":"Completed","last_update_posted":"September 14, 2020"},"NCT00678119":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment","recruitment_status":"Completed","last_update_posted":"July 15, 2013"},"NCT01582672":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)","recruitment_status":"Terminated","last_update_posted":"June 14, 2018"},"NCT01454102":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","recruitment_status":"Active, not recruiting","last_update_posted":"March 5, 2020"},"NCT02410512":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors","recruitment_status":"Completed","last_update_posted":"March 1, 2021"},"NCT02754856":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery","recruitment_status":"Active, not recruiting","last_update_posted":"January 22, 2021"},"NCT02496208":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT01688206":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","recruitment_status":"Completed","last_update_posted":"October 5, 2018"},"NCT02665416":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors","recruitment_status":"Completed","last_update_posted":"April 7, 2020"},"NCT02715531":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","recruitment_status":"Completed","last_update_posted":"July 9, 2021"},"NCT02942329":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer","recruitment_status":"Unknown","last_update_posted":"February 26, 2018"},"NCT02856425":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Trial Of Pembrolizumab And Nintedanib (PEMBIB)","recruitment_status":"Recruiting","last_update_posted":"April 7, 2020"},"NCT03081494":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer","recruitment_status":"Completed","last_update_posted":"December 11, 2020"},"NCT01472081":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)","recruitment_status":"Active, not recruiting","last_update_posted":"April 22, 2020"},"NCT02959554":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH)","recruitment_status":"Terminated","last_update_posted":"September 8, 2021"},"NCT02777710":{"publications":["29508855","30660727"],"projects":["1U01CA224348-01","1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)","recruitment_status":"Completed","last_update_posted":"September 5, 2021"},"NCT02471716":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002)","recruitment_status":"Completed","last_update_posted":"August 31, 2021"},"NCT02141295":{"publications":["29508855"],"projects":["1U01CA224348-01"],"title":"A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (McCAVE)","recruitment_status":"Terminated","last_update_posted":"March 25, 2020"},"NCT02744287":{"publications":["29590011"],"projects":["3R01CA163915-07S1"],"title":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"April 26, 2021"},"NCT02743611":{"publications":["29590011"],"projects":["3R01CA163915-07S1"],"title":"Safety &amp; Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"April 27, 2020"},"NCT01831505":{"publications":["29606314"],"projects":["1U01CA224348-01"],"title":"Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents","recruitment_status":"Completed","last_update_posted":"February 27, 2017"},"NCT03056599":{"publications":["29606314"],"projects":["1U01CA224348-01"],"title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","recruitment_status":"Recruiting","last_update_posted":"February 12, 2021"},"NCT03127631":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICALPC)","recruitment_status":"Unknown","last_update_posted":"August 28, 2018"},"NCT02907021":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2 (SCHOLAR)","recruitment_status":"Completed","last_update_posted":"October 9, 2020"},"NCT02236806":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab (SAFE)","recruitment_status":"Active, not recruiting","last_update_posted":"January 7, 2021"},"NCT01904903":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)","recruitment_status":"Completed","last_update_posted":"February 2, 2021"},"NCT03265574":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? (PROACT)","recruitment_status":"Recruiting","last_update_posted":"July 17, 2020"},"NCT01968200":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Prevention of Anthracycline-induced Cardiotoxicity (ICOS-ONE)","recruitment_status":"Active, not recruiting","last_update_posted":"August 13, 2021"},"NCT01009918":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Lisinopril or Coreg CR&#174; in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab","recruitment_status":"Completed","last_update_posted":"March 30, 2021"},"NCT01805453":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma (ASTER)","recruitment_status":"Completed","last_update_posted":"May 8, 2020"},"NCT01754909":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Mitigation of Radiation Pneumonitis and Fibrosis","recruitment_status":"Completed","last_update_posted":"October 8, 2019"},"NCT01880528":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer","recruitment_status":"Completed","last_update_posted":"January 2, 2020"},"NCT00004230":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation","recruitment_status":"Completed","last_update_posted":"June 6, 2012"},"NCT02651415":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Phase II Study of Perindopril and Regorafenib in mCRC (PARICCA)","recruitment_status":"Completed","last_update_posted":"September 12, 2019"},"NCT01705392":{"publications":["29610292"],"projects":["1U01CA224348-01"],"title":"Bevacizumab vs Dacarbazine in Metastatic Melanoma","recruitment_status":"Terminated","last_update_posted":"February 24, 2017"},"NCT00410059":{"publications":["29613856"],"projects":["1U54CA224081-01"],"title":"BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC","recruitment_status":"Completed","last_update_posted":"August 2, 2017"},"NCT00411671":{"publications":["29613856"],"projects":["1U54CA224081-01"],"title":"BATTLE Program: Sorafenib in Patients With NSCLC","recruitment_status":"Completed","last_update_posted":"February 11, 2016"},"NCT02122913":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer","recruitment_status":"Completed","last_update_posted":"May 12, 2021"},"NCT02637687":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT02576431":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)","recruitment_status":"Recruiting","last_update_posted":"September 8, 2021"},"NCT03213704":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT03215511":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 13, 2021"},"NCT02097810":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)","recruitment_status":"Completed","last_update_posted":"June 9, 2021"},"NCT02568267":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)","recruitment_status":"Recruiting","last_update_posted":"August 30, 2021"},"NCT02650401":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)","recruitment_status":"Recruiting","last_update_posted":"August 17, 2021"},"NCT03093116":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)","recruitment_status":"Recruiting","last_update_posted":"February 1, 2021"},"NCT02920996":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Merestinib In Non-Small Cell Lung Cancer And Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"August 31, 2021"},"NCT02675491":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"January 13, 2021"},"NCT02279433":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b","recruitment_status":"Completed","last_update_posted":"September 22, 2020"},"NCT01804530":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors","recruitment_status":"Terminated","last_update_posted":"August 2, 2018"},"NCT02219711":{"publications":["29880008"],"projects":["1U54CA224079-01"],"title":"Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"January 30, 2020"},"NCT02184195":{"publications":["29903880"],"projects":["1U01CA224146-01"],"title":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)","recruitment_status":"Active, not recruiting","last_update_posted":"June 18, 2021"},"NCT01482962":{"publications":["29921838"],"projects":["1U54CA224079-01"],"title":"Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma","recruitment_status":"Completed","last_update_posted":"July 31, 2018"},"NCT03066648":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS","recruitment_status":"Active, not recruiting","last_update_posted":"July 30, 2021"},"NCT03381118":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients","recruitment_status":"Terminated","last_update_posted":"April 5, 2019"},"NCT01096602":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission","recruitment_status":"Active, not recruiting","last_update_posted":"August 3, 2021"},"NCT01822509":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant","recruitment_status":"Completed","last_update_posted":"June 24, 2021"},"NCT01919619":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"August 13, 2021"},"NCT01953692":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","recruitment_status":"Completed","last_update_posted":"August 4, 2021"},"NCT02117219":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome","recruitment_status":"Completed","last_update_posted":"May 10, 2019"},"NCT02275533":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy","recruitment_status":"Active, not recruiting","last_update_posted":"September 2, 2021"},"NCT02397720":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia","recruitment_status":"Recruiting","last_update_posted":"January 15, 2021"},"NCT02464657":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)","recruitment_status":"Completed","last_update_posted":"June 18, 2020"},"NCT02530463":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome","recruitment_status":"Recruiting","last_update_posted":"January 15, 2021"},"NCT02532231":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Nivolumab in AML in Remission at High Risk for Relapse","recruitment_status":"Recruiting","last_update_posted":"February 13, 2020"},"NCT02599649":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)","recruitment_status":"Terminated","last_update_posted":"January 14, 2020"},"NCT02708641":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients &#8805; 60 With AML","recruitment_status":"Completed","last_update_posted":"August 10, 2021"},"NCT02768792":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT02771197":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT02775903":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)","recruitment_status":"Active, not recruiting","last_update_posted":"August 23, 2021"},"NCT02845297":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (&#8805;65 Years) AML Patients","recruitment_status":"Active, not recruiting","last_update_posted":"May 19, 2021"},"NCT02846376":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2020"},"NCT02890329":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","recruitment_status":"Recruiting","last_update_posted":"September 8, 2021"},"NCT02935361":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed","recruitment_status":"Active, not recruiting","last_update_posted":"April 6, 2021"},"NCT02936752":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents","recruitment_status":"Active, not recruiting","last_update_posted":"July 2, 2021"},"NCT02953561":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia","recruitment_status":"Terminated","last_update_posted":"October 22, 2020"},"NCT02981914":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation","recruitment_status":"Recruiting","last_update_posted":"June 30, 2021"},"NCT02985554":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies","recruitment_status":"Terminated","last_update_posted":"June 25, 2020"},"NCT02996474":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia","recruitment_status":"Completed","last_update_posted":"June 9, 2020"},"NCT03059485":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission","recruitment_status":"Recruiting","last_update_posted":"October 22, 2020"},"NCT03092674":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT03094637":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome","recruitment_status":"Recruiting","last_update_posted":"May 17, 2019"},"NCT03146468":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation (NIVALLO)","recruitment_status":"Active, not recruiting","last_update_posted":"September 28, 2020"},"NCT03154827":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study","recruitment_status":"Terminated","last_update_posted":"May 18, 2020"},"NCT03259516":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Nivolumab With Chemotherapy in Refractory MDS","recruitment_status":"Terminated","last_update_posted":"April 5, 2019"},"NCT03286114":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab","recruitment_status":"Recruiting","last_update_posted":"May 27, 2021"},"NCT03291353":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"April 19, 2019"},"NCT03358719":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"June 2, 2021"},"NCT03390296":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","recruitment_status":"Recruiting","last_update_posted":"February 12, 2021"},"NCT03395873":{"publications":["29951373"],"projects":["1U54CA224019-01"],"title":"Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy","recruitment_status":"Terminated","last_update_posted":"August 21, 2019"},"NCT02233595":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Evaluation of Rectal Cancer Treatment Response Using PET/MRI (Rectal PET/MRI)","recruitment_status":"Terminated","last_update_posted":"August 13, 2019"},"NCT02902757":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma","recruitment_status":"Recruiting","last_update_posted":"February 4, 2021"},"NCT02773238":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging","recruitment_status":"Active, not recruiting","last_update_posted":"July 9, 2021"},"NCT02492867":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"February 10, 2021"},"NCT00574353":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients","recruitment_status":"Withdrawn","last_update_posted":"April 8, 2020"},"NCT02016872":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients","recruitment_status":"Active, not recruiting","last_update_posted":"January 5, 2021"},"NCT01212354":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT (Escalox)","recruitment_status":"Recruiting","last_update_posted":"February 9, 2016"},"NCT01507428":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"April 29, 2021"},"NCT01542177":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"December 16, 2019"},"NCT01549730":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Cervix Hypoxia FAZA","recruitment_status":"Active, not recruiting","last_update_posted":"April 13, 2021"},"NCT02328300":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"November 14, 2018"},"NCT02456246":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (SBRT FLT-PET)","recruitment_status":"Active, not recruiting","last_update_posted":"April 29, 2021"},"NCT01666808":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"FACBC Outcomes for Post Prostatectomy","recruitment_status":"Active, not recruiting","last_update_posted":"February 2, 2021"},"NCT03115333":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma","recruitment_status":"Recruiting","last_update_posted":"May 21, 2020"},"NCT02031250":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"January 28, 2021"},"NCT03151642":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION","recruitment_status":"Completed","last_update_posted":"April 26, 2021"},"NCT02497573":{"publications":["29966725"],"projects":["1R33CA225310-01"]},"NCT00581906":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"March 2, 2021"},"NCT02319239":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Prostate Cancer Stereotactic Radiotherapy (ESKO)","recruitment_status":"Completed","last_update_posted":"October 28, 2020"},"NCT02233374":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET (PRISM)","recruitment_status":"Completed","last_update_posted":"September 18, 2019"},"NCT02415816":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas","recruitment_status":"Recruiting","last_update_posted":"January 7, 2021"},"NCT01992861":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer","recruitment_status":"Recruiting","last_update_posted":"August 24, 2021"},"NCT02137759":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"MRSI to Predict Response to RT/TMZ &#177; Belinostat in GBM","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT01507506":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma (SPECTRO GLIO)","recruitment_status":"Terminated","last_update_posted":"January 12, 2021"},"NCT03137888":{"publications":["29966725"],"projects":["1R33CA225310-01"],"title":"Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"March 1, 2021"},"NCT01727076":{"publications":["30045932"],"projects":["2UM1CA154967-07"],"title":"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"September 15, 2017"},"NCT01781429":{"publications":["30065098"],"projects":["1U54CA224083-01"],"title":"Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies","recruitment_status":"Completed","last_update_posted":"March 20, 2020"},"NCT02608229":{"publications":["30065098"],"projects":["1U54CA224083-01"],"title":"BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer","recruitment_status":"Terminated","last_update_posted":"April 21, 2021"},"NCT01714739":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"December 14, 2020"},"NCT02083484":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)","recruitment_status":"No longer available","last_update_posted":"January 26, 2018"},"NCT01543698":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"May 10, 2021"},"NCT01072175":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212","recruitment_status":"Completed","last_update_posted":"July 5, 2019"},"NCT00949702":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma","recruitment_status":"Completed","last_update_posted":"July 25, 2017"},"NCT01783938":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)","recruitment_status":"Completed","last_update_posted":"August 13, 2021"},"NCT01006980":{"publications":["30127394"],"projects":["1R33CA225291-01","1U54CA224070-01"],"title":"A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)","recruitment_status":"Completed","last_update_posted":"September 28, 2016"},"NCT01231906":{"publications":["30131550"],"projects":["3R01CA204915-02S1"],"title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"May 6, 2021"},"NCT02259621":{"publications":["30175050"],"projects":["1U01CA224348-01"],"title":"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)","recruitment_status":"Recruiting","last_update_posted":"July 27, 2021"},"NCT00106015":{"publications":["30266775"],"projects":["1R01CA211723-01A1"],"title":"Diamond Blackfan Anemia Registry (DBAR) (DBAR)","recruitment_status":"Recruiting","last_update_posted":"March 4, 2021"},"NCT02996500":{"publications":["30279971"],"projects":["1U54CA224019-01"],"title":"Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate","recruitment_status":"Completed","last_update_posted":"February 27, 2020"},"NCT03328078":{"publications":["30279971","32961746"],"projects":["1U54CA224019-01","1U54CA224083-01"],"title":"A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies","recruitment_status":"Recruiting","last_update_posted":"May 5, 2021"},"NCT02891603":{"publications":["30279971"],"projects":["1U54CA224019-01"],"title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","recruitment_status":"Recruiting","last_update_posted":"August 18, 2021"},"NCT01235871":{"publications":["30279971"],"projects":["1U54CA224019-01"],"title":"A Single and Multiple-Dose Study of SB1578","recruitment_status":"Completed","last_update_posted":"April 20, 2012"},"NCT01728402":{"publications":["30333627","30642575"],"projects":["1U54CA224019-01"],"title":"Pathogenesis of Hematologic Malignancies","recruitment_status":"Enrolling by invitation","last_update_posted":"August 30, 2021"},"NCT03456700":{"publications":["30401714"],"projects":["3U54CA224065-01S1"],"title":"Auranofin and Sirolimus in Treating Participants With Ovarian Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"March 16, 2021"},"NCT01195922":{"publications":["30420444","30894372"],"projects":["1R33CA225291-01"],"title":"Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma","recruitment_status":"Completed","last_update_posted":"December 6, 2017"},"NCT01657682":{"publications":["30541869","30651561"],"projects":["3R01CA182543-05S2","1U54CA224019-01"],"title":"A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations","recruitment_status":"Completed","last_update_posted":"July 20, 2020"},"NCT03123783":{"publications":["30552023"],"projects":["1U01CA224348-01"],"title":"CD40 Agonistic Antibody APX005M in Combination With Nivolumab","recruitment_status":"Completed","last_update_posted":"May 4, 2021"},"NCT02376699":{"publications":["30552023"],"projects":["1U01CA224348-01"],"title":"Safety Study of SEA-CD40 in Cancer Patients","recruitment_status":"Active, not recruiting","last_update_posted":"March 16, 2021"},"NCT03270176":{"publications":["30552023"],"projects":["1U01CA224348-01"]},"NCT01502293":{"publications":["30552023"],"projects":["1U01CA224348-01"],"title":"Trial of pIL-12 Electroporation Malignant Melanoma (IL-12MEL)","recruitment_status":"Completed","last_update_posted":"October 9, 2019"},"NCT02698189":{"publications":["30642575","33371192"],"projects":["1U54CA224019-01","5R01CA176745-09"],"title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)","recruitment_status":"Active, not recruiting","last_update_posted":"July 13, 2021"},"NCT02308761":{"publications":["30642575","33371192"],"projects":["1U54CA224019-01","5R01CA176745-09"],"title":"A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome","recruitment_status":"Completed","last_update_posted":"December 11, 2017"},"NCT02391480":{"publications":["30642575"],"projects":["1U54CA224019-01"],"title":"A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer","recruitment_status":"Completed","last_update_posted":"November 29, 2019"},"NCT02683395":{"publications":["30642575"],"projects":["1U54CA224019-01"],"title":"A Study of PLX51107 in Advanced Malignancies","recruitment_status":"Terminated","last_update_posted":"December 24, 2018"},"NCT02606123":{"publications":["30644358"],"projects":["1U54CA224079-01"],"title":"Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Terminated","last_update_posted":"March 1, 2018"},"NCT02339558":{"publications":["30651320"],"projects":["2UM1CA154967-07"],"title":"Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer","recruitment_status":"Completed","last_update_posted":"September 13, 2019"},"NCT01522469":{"publications":["30651561"],"projects":["1U54CA224019-01"],"title":"Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations","recruitment_status":"Completed","last_update_posted":"June 28, 2018"},"NCT02639026":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers","recruitment_status":"Active, not recruiting","last_update_posted":"March 9, 2021"},"NCT02648282":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 9, 2021"},"NCT03245541":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"August 9, 2021"},"NCT03190265":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"August 20, 2021"},"NCT02451982":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"March 22, 2021"},"NCT03153410":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","recruitment_status":"Active, not recruiting","last_update_posted":"August 19, 2021"},"NCT03006302":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","recruitment_status":"Recruiting","last_update_posted":"August 20, 2021"},"NCT03214250":{"publications":["30660727","31158393"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 30, 2021"},"NCT02758587":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)","recruitment_status":"Recruiting","last_update_posted":"March 19, 2018"},"NCT02546531":{"publications":["30660727","34025067"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01","1U54CA224083-01"],"title":"Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer","recruitment_status":"Completed","last_update_posted":"July 20, 2021"},"NCT03481920":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer","recruitment_status":"Terminated","last_update_posted":"August 22, 2019"},"NCT03193190":{"publications":["30660727","31158393"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT03634332":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC","recruitment_status":"Unknown","last_update_posted":"May 7, 2019"},"NCT02436668":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)","recruitment_status":"Completed","last_update_posted":"December 30, 2020"},"NCT03496662":{"publications":["30660727"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","recruitment_status":"Recruiting","last_update_posted":"July 23, 2021"},"NCT03404960":{"publications":["30660727","31158393"],"projects":["1U01CA224146-01","1U01CA224175-01","1U01CA224193-01"],"title":"Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)","recruitment_status":"Recruiting","last_update_posted":"June 10, 2021"},"NCT00798213":{"publications":["30665374"],"projects":["1U24CA224067-01"],"title":"SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)","recruitment_status":"Terminated","last_update_posted":"February 4, 2015"},"NCT00937937":{"publications":["30665374"],"projects":["1U24CA224067-01"],"title":"Dinaciclib in Treating Patients With Stage IV Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT03253679":{"publications":["30665374"],"projects":["1U24CA224067-01"],"title":"AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 16, 2021"},"NCT03271372":{"publications":["30726175"],"projects":["2UM1CA154967-07"],"title":"Adjuvant Avelumab in Merkel Cell Cancer (ADAM)","recruitment_status":"Recruiting","last_update_posted":"May 27, 2021"},"NCT02488759":{"publications":["30726175"],"projects":["2UM1CA154967-07"],"title":"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2020"},"NCT01659151":{"publications":["30765391"],"projects":["1U54CA224070-01"],"title":"Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02974725":{"publications":["30770389"],"projects":["1U54CA224068-01"],"title":"A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma","recruitment_status":"Recruiting","last_update_posted":"September 8, 2021"},"NCT03478397":{"publications":["30808379","32032940","33264086"],"projects":["1R01CA218306-01"],"title":"Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)","recruitment_status":"Completed","last_update_posted":"April 6, 2021"},"NCT02358031":{"publications":["30814108","31340724"],"projects":["1R33CA225291-01","1U01DE028227-01","1U01DE029255-01"],"title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","recruitment_status":"Active, not recruiting","last_update_posted":"October 23, 2020"},"NCT02741570":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT00771641":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"January 24, 2014"},"NCT03383094":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer","recruitment_status":"Recruiting","last_update_posted":"February 8, 2021"},"NCT03317327":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)","recruitment_status":"Recruiting","last_update_posted":"September 30, 2019"},"NCT03546582":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)","recruitment_status":"Recruiting","last_update_posted":"August 3, 2021"},"NCT02296684":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 30, 2021"},"NCT03051906":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)","recruitment_status":"Not yet recruiting","last_update_posted":"November 22, 2017"},"NCT02999087":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)","recruitment_status":"Active, not recruiting","last_update_posted":"November 4, 2020"},"NCT02764593":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 3, 2021"},"NCT03247712":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"May 20, 2021"},"NCT03673735":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 10, 2021"},"NCT03529422":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN","recruitment_status":"Recruiting","last_update_posted":"May 11, 2021"},"NCT03426657":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC","recruitment_status":"Recruiting","last_update_posted":"June 11, 2021"},"NCT03509012":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)","recruitment_status":"Active, not recruiting","last_update_posted":"July 21, 2021"},"NCT03539198":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"April 5, 2021"},"NCT03085719":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN","recruitment_status":"Recruiting","last_update_posted":"November 13, 2020"},"NCT03283605":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas","recruitment_status":"Recruiting","last_update_posted":"May 27, 2021"},"NCT03313804":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Priming Immunotherapy in Advanced Disease With Radiation","recruitment_status":"Recruiting","last_update_posted":"June 14, 2021"},"NCT02777385":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer","recruitment_status":"Recruiting","last_update_posted":"April 6, 2021"},"NCT03349710":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"August 9, 2021"},"NCT02892201":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Pembrolizumab in HNSCC With Residual Disease After Radiation","recruitment_status":"Active, not recruiting","last_update_posted":"July 15, 2021"},"NCT02841748":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study","recruitment_status":"Recruiting","last_update_posted":"January 7, 2021"},"NCT03040999":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT02952586":{"publications":["30814108","33368875"],"projects":["1R33CA225291-01","1U01DE028227-01","1U01DE029188-01"],"title":"Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)","recruitment_status":"Terminated","last_update_posted":"June 22, 2021"},"NCT03452137":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Recruiting","last_update_posted":"August 5, 2021"},"NCT01302834":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"February 23, 2021"},"NCT01040832":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"January 30, 2017"},"NCT01334177":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck","recruitment_status":"Completed","last_update_posted":"March 5, 2015"},"NCT01360827":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Terminated","last_update_posted":"June 17, 2014"},"NCT01468896":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","recruitment_status":"Active, not recruiting","last_update_posted":"March 22, 2021"},"NCT01836029":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"October 29, 2019"},"NCT01935921":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02110082":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 19, 2017"},"NCT02124850":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab","recruitment_status":"Terminated","last_update_posted":"October 25, 2019"},"NCT02633800":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )","recruitment_status":"Terminated","last_update_posted":"January 7, 2019"},"NCT02643550":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Active, not recruiting","last_update_posted":"February 9, 2021"},"NCT02938273":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","recruitment_status":"Completed","last_update_posted":"December 11, 2019"},"NCT03082534":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"March 11, 2021"},"NCT03370276":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03494322":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)","recruitment_status":"Active, not recruiting","last_update_posted":"November 5, 2020"},"NCT03498378":{"publications":["30814108","30842677"],"projects":["1R33CA225291-01","1U01DE028227-01","1U01CA233100-01"],"title":"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"October 19, 2020"},"NCT01860430":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02581137":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03074513":{"publications":["30814108"],"projects":["1R33CA225291-01","1U01DE028227-01"],"title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"February 24, 2021"},"NCT02950766":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"NeoVax Plus Ipilimumab in Renal Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"March 3, 2021"},"NCT03422094":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","recruitment_status":"Terminated","last_update_posted":"April 23, 2021"},"NCT03361852":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma","recruitment_status":"Not yet recruiting","last_update_posted":"August 25, 2021"},"NCT03219450":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"A Personalized Neoantigen Cancer Vaccine in Treatment Na&#239;ve, Asymptomatic Patients With IGHV Unmutated CLL.","recruitment_status":"Not yet recruiting","last_update_posted":"August 26, 2021"},"NCT03063632":{"publications":["30842677"],"projects":["2UM1CA154967-07","1U01CA233100-01"],"title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"May 14, 2021"},"NCT02614456":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"November 29, 2019"},"NCT02646748":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"December 4, 2020"},"NCT03012230":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer","recruitment_status":"Recruiting","last_update_posted":"May 25, 2021"},"NCT03425006":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Pembrolizumab and Itacitinib (INCB039110) for NSCLC","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03172936":{"publications":["30842677","32541866"],"projects":["1U01CA233100-01","1U54CA244719-01"],"title":"Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","recruitment_status":"Completed","last_update_posted":"February 24, 2021"},"NCT03147287":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Palbociclib After CDK and Endocrine Therapy (PACE)","recruitment_status":"Recruiting","last_update_posted":"August 23, 2021"},"NCT03573648":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)","recruitment_status":"Recruiting","last_update_posted":"June 2, 2021"},"NCT03294694":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"December 29, 2020"},"NCT02779751":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"March 4, 2021"},"NCT02947165":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.","recruitment_status":"Completed","last_update_posted":"July 8, 2021"},"NCT02734160":{"publications":["30842677","34025067"],"projects":["1U01CA233100-01","1U54CA224083-01"],"title":"A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"August 5, 2019"},"NCT02423343":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","recruitment_status":"Completed","last_update_posted":"September 9, 2021"},"NCT02517398":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"March 22, 2021"},"NCT03620201":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer","recruitment_status":"Recruiting","last_update_posted":"June 4, 2020"},"NCT03631706":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)","recruitment_status":"Active, not recruiting","last_update_posted":"October 20, 2020"},"NCT02675439":{"publications":["30842677"],"projects":["1U01CA233100-01"],"title":"Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas","recruitment_status":"Active, not recruiting","last_update_posted":"July 9, 2020"},"NCT03010176":{"publications":["30842677","32541866"],"projects":["1U01CA233100-01","1U54CA244719-01"],"title":"Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)","recruitment_status":"Active, not recruiting","last_update_posted":"April 21, 2021"},"NCT02457910":{"publications":["30889376"],"projects":["1U2CCA233280-01"],"title":"Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"February 23, 2021"},"NCT02456857":{"publications":["30889376"],"projects":["1U2CCA233280-01"],"title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","recruitment_status":"Active, not recruiting","last_update_posted":"April 13, 2021"},"NCT03805399":{"publications":["30889376"],"projects":["1U2CCA233280-01"],"title":"FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)","recruitment_status":"Recruiting","last_update_posted":"February 5, 2020"},"NCT03487666":{"publications":["30889376"],"projects":["1U2CCA233280-01"],"title":"OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT01042379":{"publications":["30889376"],"projects":["1U2CCA233280-01"],"title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)","recruitment_status":"Recruiting","last_update_posted":"August 27, 2021"},"NCT03801369":{"publications":["30889376"],"projects":["1U2CCA233280-01"],"title":"Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer","recruitment_status":"Recruiting","last_update_posted":"June 11, 2021"},"NCT01023386":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer","recruitment_status":"Completed","last_update_posted":"April 13, 2010"},"NCT00818480":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155","recruitment_status":"Completed","last_update_posted":"September 4, 2015"},"NCT01007292":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment","recruitment_status":"Completed","last_update_posted":"October 19, 2015"},"NCT01009775":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma","recruitment_status":"Completed","last_update_posted":"September 4, 2015"},"NCT01038804":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer","recruitment_status":"Completed","last_update_posted":"September 18, 2013"},"NCT00498914":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects","recruitment_status":"Terminated","last_update_posted":"September 4, 2015"},"NCT01100931":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)","recruitment_status":"Completed","last_update_posted":"October 19, 2015"},"NCT00514267":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors","recruitment_status":"Completed","last_update_posted":"August 13, 2015"},"NCT00281541":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma","recruitment_status":"Completed","last_update_posted":"June 7, 2012"},"NCT00328588":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy","recruitment_status":"Completed","last_update_posted":"January 2, 2008"},"NCT00257478":{"publications":["30909651"],"projects":["1U54CA231652-01"],"title":"A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy","recruitment_status":"Completed","last_update_posted":"June 7, 2012"},"NCT01747551":{"publications":["30913304"],"projects":["1U01CA224348-01"],"title":"FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer","recruitment_status":"Completed","last_update_posted":"February 10, 2020"},"NCT00756106":{"publications":["30948807"],"projects":["1U01CA224348-01"],"title":"MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma","recruitment_status":"Terminated","last_update_posted":"May 13, 2020"},"NCT01004172":{"publications":["30948807"],"projects":["1U01CA224348-01"],"title":"Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases","recruitment_status":"Completed","last_update_posted":"December 14, 2018"},"NCT01032122":{"publications":["30967646"],"projects":["1U54CA224068-01"],"title":"Rituximab in Metastatic Melanoma","recruitment_status":"Terminated","last_update_posted":"April 25, 2013"},"NCT01376713":{"publications":["30967646","31519915"],"projects":["1U54CA224068-01","1U54CA224070-01"],"title":"Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma","recruitment_status":"Completed","last_update_posted":"October 6, 2015"},"NCT01307267":{"publications":["30967646"],"projects":["1U54CA224068-01"],"title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","recruitment_status":"Completed","last_update_posted":"March 17, 2020"},"NCT02579226":{"publications":["30979745"],"projects":["3R01CA204915-02S1"],"title":"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.","recruitment_status":"Completed","last_update_posted":"May 1, 2020"},"NCT03630120":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer","recruitment_status":"Terminated","last_update_posted":"July 14, 2021"},"NCT03543969":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT03511196":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"July 19, 2021"},"NCT02415621":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"May 24, 2021"},"NCT03227926":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance (CHRONOS)","recruitment_status":"Active, not recruiting","last_update_posted":"August 31, 2021"},"NCT03259009":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) (RASINTRO)","recruitment_status":"Unknown","last_update_posted":"September 11, 2017"},"NCT02296203":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)","recruitment_status":"Unknown","last_update_posted":"February 15, 2018"},"NCT01158521":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer","recruitment_status":"Completed","last_update_posted":"September 12, 2018"},"NCT03088930":{"publications":["30992280","32822576"],"projects":["1U54CA224081-01"],"title":"Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer","recruitment_status":"Completed","last_update_posted":"April 23, 2021"},"NCT03433469":{"publications":["30992280","32822576"],"projects":["1U54CA224081-01"],"title":"Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery","recruitment_status":"Recruiting","last_update_posted":"June 3, 2021"},"NCT02443948":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)","recruitment_status":"Unknown","last_update_posted":"February 14, 2017"},"NCT03691012":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Circulating Tumour DNA as a Marker of Residual Disease &amp; Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer","recruitment_status":"Recruiting","last_update_posted":"November 3, 2020"},"NCT02245100":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 1, 2021"},"NCT03637686":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer (IMPROVE)","recruitment_status":"Recruiting","last_update_posted":"January 14, 2021"},"NCT02883517":{"publications":["30992280"],"projects":["1U54CA224081-01"],"title":"Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA)","recruitment_status":"Unknown","last_update_posted":"February 23, 2017"},"NCT03414034":{"publications":["31040125"],"projects":["3U54CA224065-01S1"],"title":"Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 23, 2021"},"NCT03303339":{"publications":["31040125"],"projects":["3U54CA224065-01S1"],"title":"Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)","recruitment_status":"Active, not recruiting","last_update_posted":"May 27, 2021"},"NCT02864992":{"publications":["31040125"],"projects":["3U54CA224065-01S1"],"title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","recruitment_status":"Active, not recruiting","last_update_posted":"June 11, 2021"},"NCT02952534":{"publications":["31061129"],"projects":["1U54CA224079-01"],"title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)","recruitment_status":"Completed","last_update_posted":"August 30, 2021"},"NCT02987543":{"publications":["31061129"],"projects":["1U54CA224079-01"],"title":"Study of Olaparib (Lynparza&#8482;) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","recruitment_status":"Active, not recruiting","last_update_posted":"August 4, 2021"},"NCT02854436":{"publications":["31061129"],"projects":["1U54CA224079-01"],"title":"An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2021"},"NCT02525068":{"publications":["31061129"],"projects":["1U54CA224079-01"],"title":"A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)","recruitment_status":"Unknown","last_update_posted":"August 8, 2018"},"NCT03310541":{"publications":["31061129"],"projects":["1U54CA224079-01"],"title":"AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations","recruitment_status":"Active, not recruiting","last_update_posted":"July 6, 2021"},"NCT01747486":{"publications":["31076448"],"projects":["1R01CA226983-01"],"title":"Dose Optimization Trial of CD19 Redirected Autologous T Cells","recruitment_status":"Completed","last_update_posted":"August 30, 2019"},"NCT01029366":{"publications":["31076448"],"projects":["1R01CA226983-01"],"title":"CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy","recruitment_status":"Completed","last_update_posted":"June 26, 2019"},"NCT01821729":{"publications":["31145418","34025067"],"projects":["1U01CA224348-01","1U54CA224083-01"],"title":"Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 25, 2020"},"NCT03563248":{"publications":["31145418","34025067"],"projects":["1U01CA224348-01","1U54CA224083-01"],"title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"January 20, 2021"},"NCT02595866":{"publications":["31154457","33608378"],"projects":["2UM1CA154967-07"],"title":"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms","recruitment_status":"Recruiting","last_update_posted":"August 5, 2021"},"NCT02639546":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)","recruitment_status":"Active, not recruiting","last_update_posted":"July 2, 2021"},"NCT03095248":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)","recruitment_status":"Recruiting","last_update_posted":"July 23, 2021"},"NCT02523014":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 17, 2021"},"NCT02831257":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","recruitment_status":"Completed","last_update_posted":"December 22, 2020"},"NCT03071874":{"publications":["31161239"],"projects":["1U2CCA233262-01"],"title":"Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas","recruitment_status":"Active, not recruiting","last_update_posted":"January 20, 2021"},"NCT03744247":{"publications":["31378984"],"projects":["1U01CA224348-01"],"title":"Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 2, 2019"},"NCT03434379":{"publications":["31378984"],"projects":["1U01CA224348-01"],"title":"A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] (IMbrave150)","recruitment_status":"Active, not recruiting","last_update_posted":"July 22, 2021"},"NCT01140347":{"publications":["31378984"],"projects":["1U01CA224348-01"],"title":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)","recruitment_status":"Completed","last_update_posted":"December 28, 2015"},"NCT02435433":{"publications":["31378984"],"projects":["1U01CA224348-01"],"title":"A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)","recruitment_status":"Active, not recruiting","last_update_posted":"July 30, 2021"},"NCT02060188":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)","recruitment_status":"Active, not recruiting","last_update_posted":"November 6, 2019"},"NCT02460198":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)","recruitment_status":"Completed","last_update_posted":"March 22, 2021"},"NCT03631641":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy","recruitment_status":"Active, not recruiting","last_update_posted":"May 15, 2020"},"NCT01461148":{"publications":["31383734","33842408"],"projects":["1U01CA233056-01","1U01CA233097-01"],"title":"Vaccination Against MSI Colorectal Cancer","recruitment_status":"Completed","last_update_posted":"June 23, 2015"},"NCT01885702":{"publications":["31383734"],"projects":["1U01CA233056-01"],"title":"Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI","recruitment_status":"Active, not recruiting","last_update_posted":"December 9, 2020"},"NCT02657005":{"publications":["31392992"],"projects":["3R01CA204915-02S1"],"title":"TK216 in Patients With Relapsed or Refractory Ewing Sarcoma","recruitment_status":"Recruiting","last_update_posted":"August 23, 2021"},"NCT00070109":{"publications":["31392992"],"projects":["3R01CA204915-02S1"],"title":"Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors","recruitment_status":"Completed","last_update_posted":"September 14, 2018"},"NCT03600649":{"publications":["31392992","32842875"],"projects":["3R01CA204915-02S1","1U54CA231641-01"],"title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","recruitment_status":"Recruiting","last_update_posted":"August 11, 2021"},"NCT03637491":{"publications":["31409394"],"projects":["1U01DE028233-01"],"title":"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors","recruitment_status":"Terminated","last_update_posted":"July 23, 2021"},"NCT03598270":{"publications":["31409394"],"projects":["1U01DE028233-01"],"title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)","recruitment_status":"Recruiting","last_update_posted":"August 13, 2021"},"NCT01240538":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors","recruitment_status":"Completed","last_update_posted":"May 13, 2014"},"NCT01048892":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features","recruitment_status":"Completed","last_update_posted":"January 30, 2014"},"NCT02457845":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"July 8, 2021"},"NCT03043391":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","recruitment_status":"Active, not recruiting","last_update_posted":"July 13, 2021"},"NCT02756845":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors","recruitment_status":"Recruiting","last_update_posted":"August 19, 2021"},"NCT00931931":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors","recruitment_status":"Completed","last_update_posted":"March 21, 2018"},"NCT01326104":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)","recruitment_status":"Active, not recruiting","last_update_posted":"August 11, 2021"},"NCT02932956":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)","recruitment_status":"Recruiting","last_update_posted":"January 8, 2021"},"NCT03500991":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors","recruitment_status":"Recruiting","last_update_posted":"March 15, 2021"},"NCT03638167":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors","recruitment_status":"Recruiting","last_update_posted":"March 15, 2021"},"NCT02315612":{"publications":["31650024","31828566"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT02772198":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"November 3, 2020"},"NCT01555892":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)","recruitment_status":"Recruiting","last_update_posted":"December 23, 2020"},"NCT02892695":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma","recruitment_status":"Unknown","last_update_posted":"December 6, 2016"},"NCT02573896":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","recruitment_status":"Recruiting","last_update_posted":"January 20, 2021"},"NCT02650648":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"October 5, 2020"},"NCT03209869":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 5, 2021"},"NCT03420963":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"April 29, 2021"},"NCT02100891":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)","recruitment_status":"Active, not recruiting","last_update_posted":"March 24, 2021"},"NCT01823198":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"December 4, 2020"},"NCT01904136":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"February 10, 2021"},"NCT02809092":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia","recruitment_status":"Unknown","last_update_posted":"October 15, 2019"},"NCT01898793":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","recruitment_status":"Recruiting","last_update_posted":"May 21, 2021"},"NCT01619761":{"publications":["31650024"],"projects":["1U01CA232488-01","1U54CA232561-01A1"],"title":"NK Cells in Cord Blood Transplantation","recruitment_status":"Active, not recruiting","last_update_posted":"February 11, 2020"},"NCT01084252":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"April 20, 2021"},"NCT03733717":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"August 2, 2021"},"NCT02812706":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients (Islands)","recruitment_status":"Active, not recruiting","last_update_posted":"September 29, 2020"},"NCT02514668":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"March 26, 2021"},"NCT02960555":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma","recruitment_status":"Recruiting","last_update_posted":"May 13, 2021"},"NCT01749969":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","recruitment_status":"Active, not recruiting","last_update_posted":"March 26, 2021"},"NCT02283775":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)","recruitment_status":"Completed","last_update_posted":"July 9, 2021"},"NCT02990338":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)","recruitment_status":"Active, not recruiting","last_update_posted":"February 24, 2021"},"NCT02332850":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"July 21, 2021"},"NCT03275285":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)","recruitment_status":"Active, not recruiting","last_update_posted":"June 9, 2021"},"NCT03319667":{"publications":["31779273","32054831"],"projects":["2P01CA155258-06"],"title":"Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)","recruitment_status":"Active, not recruiting","last_update_posted":"July 12, 2021"},"NCT03617731":{"publications":["31779273","32054831"],"projects":["2P01CA155258-06"],"title":"Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","recruitment_status":"Active, not recruiting","last_update_posted":"October 8, 2020"},"NCT03104842":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","recruitment_status":"Active, not recruiting","last_update_posted":"February 3, 2021"},"NCT03194867":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients","recruitment_status":"Active, not recruiting","last_update_posted":"March 26, 2021"},"NCT04083898":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"April 5, 2021"},"NCT02513186":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","recruitment_status":"Active, not recruiting","last_update_posted":"June 4, 2020"},"NCT04045795":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","recruitment_status":"Recruiting","last_update_posted":"June 3, 2021"},"NCT02413489":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma","recruitment_status":"Terminated","last_update_posted":"June 26, 2018"},"NCT02927925":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type","recruitment_status":"Completed","last_update_posted":"January 14, 2021"},"NCT02999633":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)","recruitment_status":"Terminated","last_update_posted":"January 18, 2020"},"NCT03860844":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS)","recruitment_status":"Recruiting","last_update_posted":"June 8, 2021"},"NCT03499808":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","recruitment_status":"Active, not recruiting","last_update_posted":"June 10, 2021"},"NCT03769181":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study of Isatuximab-based Therapy in Participants With Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 27, 2021"},"NCT03367819":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies","recruitment_status":"Completed","last_update_posted":"April 21, 2021"},"NCT03637764":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"November 25, 2020"},"NCT03555149":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","recruitment_status":"Recruiting","last_update_posted":"August 18, 2021"},"NCT03869190":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT03201965":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis","recruitment_status":"Active, not recruiting","last_update_posted":"August 23, 2021"},"NCT04131309":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis","recruitment_status":"Recruiting","last_update_posted":"February 5, 2021"},"NCT03473730":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"May 13, 2021"},"NCT04088903":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"October 28, 2020"},"NCT03277105":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"July 23, 2021"},"NCT01421186":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"September 16, 2020"},"NCT02219256":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants","recruitment_status":"Completed","last_update_posted":"May 3, 2017"},"NCT03439280":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)","recruitment_status":"Active, not recruiting","last_update_posted":"March 19, 2021"},"NCT03984097":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT02076009":{"publications":["31779273","33149130"],"projects":["2P01CA155258-06"],"title":"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"August 9, 2021"},"NCT02136134":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"August 24, 2021"},"NCT02252172":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"August 20, 2021"},"NCT02195479":{"publications":["31779273"],"projects":["2P01CA155258-06"],"title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"July 23, 2021"},"NCT02541383":{"publications":["31779273","32054831"],"projects":["2P01CA155258-06"],"title":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)","recruitment_status":"Active, not recruiting","last_update_posted":"December 7, 2020"},"NCT02393859":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","recruitment_status":"Active, not recruiting","last_update_posted":"December 8, 2020"},"NCT02435849":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)","recruitment_status":"Active, not recruiting","last_update_posted":"June 30, 2021"},"NCT02559778":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)","recruitment_status":"Recruiting","last_update_posted":"August 23, 2021"},"NCT03837899":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Durvalumab and Tremelimumab for Pediatric Malignancies","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT04044378":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Famitinib Plus Camrelizumab &amp; Famitinib Alone &amp; Famitinib Plus Ifosfamide in Advanced Osteosarcoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"May 19, 2020"},"NCT02311621":{"publications":["31828566","34113750"],"projects":["1U54CA232561-01A1","1U54CA232568-01"],"title":"Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01","recruitment_status":"Recruiting","last_update_posted":"April 27, 2021"},"NCT03130959":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)","recruitment_status":"Active, not recruiting","last_update_posted":"April 1, 2021"},"NCT03618381":{"publications":["31828566","32353955"],"projects":["1U54CA232561-01A1","1UG3CA244687-01"],"title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","recruitment_status":"Recruiting","last_update_posted":"April 19, 2021"},"NCT03334305":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)","recruitment_status":"Recruiting","last_update_posted":"August 12, 2021"},"NCT03448393":{"publications":["31828566","34113750"],"projects":["1U54CA232561-01A1","1U54CA232568-01"],"title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT01192555":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)","recruitment_status":"Active, not recruiting","last_update_posted":"March 10, 2021"},"NCT02502708":{"publications":["31828566","33005623"],"projects":["1U54CA232561-01A1","1U01CA224151-01"],"title":"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors","recruitment_status":"Completed","last_update_posted":"June 4, 2020"},"NCT03703050":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)","recruitment_status":"Recruiting","last_update_posted":"July 7, 2021"},"NCT03907488":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT02789228":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)","recruitment_status":"Recruiting","last_update_posted":"February 25, 2021"},"NCT03396575":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)","recruitment_status":"Recruiting","last_update_posted":"July 13, 2021"},"NCT03911388":{"publications":["31828566"],"projects":["1U54CA232561-01A1"]},"NCT03178032":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas","recruitment_status":"Active, not recruiting","last_update_posted":"July 16, 2020"},"NCT02962167":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT","recruitment_status":"Recruiting","last_update_posted":"June 30, 2021"},"NCT02444546":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT03495921":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT00790413":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Haploidentical Stem Cell Transplantation in Neuroblastoma","recruitment_status":"Active, not recruiting","last_update_posted":"February 21, 2021"},"NCT02793466":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Durvalumab in Pediatric and Adolescent Patients","recruitment_status":"Unknown","last_update_posted":"January 30, 2019"},"NCT01860937":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"July 6, 2021"},"NCT03006848":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT00634231":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"January 27, 2021"},"NCT02511132":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma","recruitment_status":"Completed","last_update_posted":"February 4, 2021"},"NCT03299309":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"May 25, 2021"},"NCT02028455":{"publications":["31828566","33914708"],"projects":["1U54CA232561-01A1","1U01CA247548-01"],"title":"A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"January 29, 2021"},"NCT03643276":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","recruitment_status":"Recruiting","last_update_posted":"July 7, 2021"},"NCT03244306":{"publications":["31828566","33914708"],"projects":["1U54CA232561-01A1","1U01CA247548-01"],"title":"A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)","recruitment_status":"Active, not recruiting","last_update_posted":"January 19, 2021"},"NCT03186118":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia","recruitment_status":"Recruiting","last_update_posted":"March 25, 2021"},"NCT03605589":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"April 1, 2021"},"NCT03330691":{"publications":["31828566","33914708","34113750"],"projects":["1U54CA232561-01A1","1U01CA247548-01","1U54CA232568-01"],"title":"A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia","recruitment_status":"Recruiting","last_update_posted":"May 24, 2021"},"NCT00902044":{"publications":["31828566","32669548"],"projects":["1U54CA232561-01A1","1U54CA232568-01"],"title":"Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 24, 2021"},"NCT03769467":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","recruitment_status":"Active, not recruiting","last_update_posted":"February 3, 2021"},"NCT02960230":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","recruitment_status":"Recruiting","last_update_posted":"August 25, 2021"},"NCT01700946":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","recruitment_status":"Completed","last_update_posted":"August 24, 2021"},"NCT01169584":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients","recruitment_status":"Completed","last_update_posted":"January 21, 2016"},"NCT03359018":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)","recruitment_status":"Completed","last_update_posted":"May 19, 2020"},"NCT02403778":{"publications":["31828566"],"projects":["1U54CA232561-01A1"],"title":"Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma","recruitment_status":"Active, not recruiting","last_update_posted":"September 23, 2020"},"NCT01130142":{"publications":["31980749","34025067"],"projects":["1U01CA224193-01","1U01CA224348-01","1U54CA224083-01"],"title":"A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"March 6, 2017"},"NCT01850628":{"publications":["31988290"],"projects":["1U54CA233223-01"],"title":"NSABP Biospecimen Discovery Project","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2020"},"NCT02424617":{"publications":["32018052"],"projects":["1U54CA224081-01"],"title":"A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","recruitment_status":"Unknown","last_update_posted":"July 6, 2017"},"NCT01091831":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects","recruitment_status":"Active, not recruiting","last_update_posted":"November 6, 2020"},"NCT02406144":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"November 30, 2017"},"NCT02253316":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"October 1, 2020"},"NCT02389517":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"January 7, 2021"},"NCT02659293":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"June 30, 2021"},"NCT02203643":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)","recruitment_status":"Active, not recruiting","last_update_posted":"April 29, 2021"},"NCT03896737":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","recruitment_status":"Recruiting","last_update_posted":"August 19, 2021"},"NCT03901963":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT02874742":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"July 12, 2021"},"NCT02495922":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)","recruitment_status":"Completed","last_update_posted":"September 10, 2021"},"NCT01850524":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"February 1, 2021"},"NCT03729804":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))","recruitment_status":"Recruiting","last_update_posted":"June 8, 2021"},"NCT03742297":{"publications":["32054831"],"projects":["2P01CA155258-06"]},"NCT03710603":{"publications":["32054831","33777050"],"projects":["2P01CA155258-06","1U01CA244291-01"],"title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)","recruitment_status":"Active, not recruiting","last_update_posted":"August 26, 2021"},"NCT03652064":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","recruitment_status":"Active, not recruiting","last_update_posted":"September 17, 2021"},"NCT01335399":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)","recruitment_status":"Active, not recruiting","last_update_posted":"October 26, 2020"},"NCT01668719":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"April 6, 2020"},"NCT02312258":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)","recruitment_status":"Active, not recruiting","last_update_posted":"November 10, 2020"},"NCT03748953":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT03720041":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)","recruitment_status":"Recruiting","last_update_posted":"June 15, 2021"},"NCT03733691":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients","recruitment_status":"Recruiting","last_update_posted":"October 27, 2020"},"NCT02891811":{"publications":["32054831"],"projects":["2P01CA155258-06"],"title":"Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy","recruitment_status":"Recruiting","last_update_posted":"May 19, 2021"},"NCT00058474":{"publications":["32091598","33345351"],"projects":["1U01CA232859-01"],"title":"Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer","recruitment_status":"Unknown","last_update_posted":"March 23, 2016"},"NCT03184571":{"publications":["32102694"],"projects":["1U24CA224316-01"],"title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC","recruitment_status":"Recruiting","last_update_posted":"May 29, 2020"},"NCT02936609":{"publications":["32294251"],"projects":["1P50CA244289-01"],"title":"Assessing Community Cancer Care After Insurance ExpanSionS (ACCESS)","recruitment_status":"Completed","last_update_posted":"August 30, 2021"},"NCT03545763":{"publications":["32294251"],"projects":["1P50CA244289-01"],"title":"Evaluating Control of Hypertension - Effect of Social Determinants (ECHOES)","recruitment_status":"Active, not recruiting","last_update_posted":"March 23, 2021"},"NCT01454297":{"publications":["32317634","32471990","32687451","33963182"],"projects":["2P01CA155258-06","1U2CCA233303-01"],"title":"Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)","recruitment_status":"Active, not recruiting","last_update_posted":"August 16, 2018"},"NCT03433183":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors","recruitment_status":"Recruiting","last_update_posted":"September 18, 2020"},"NCT02008877":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)","recruitment_status":"Completed","last_update_posted":"May 15, 2019"},"NCT02584647":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)","recruitment_status":"Recruiting","last_update_posted":"August 31, 2021"},"NCT03009201":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT02691026":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery","recruitment_status":"Terminated","last_update_posted":"June 23, 2021"},"NCT02834013":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT04222413":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT03880123":{"publications":["32353955"],"projects":["1UG3CA244687-01"],"title":"Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"November 27, 2020"},"NCT00064129":{"publications":["32376721"],"projects":["1U01CA233100-01"],"title":"Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer","recruitment_status":"Completed","last_update_posted":"July 30, 2020"},"NCT01363206":{"publications":["32376721"],"projects":["1U01CA233100-01"],"title":"Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)","recruitment_status":"Completed","last_update_posted":"March 19, 2020"},"NCT03799432":{"publications":["32391524"],"projects":["1P50CA244431-01"],"title":"Collaborative Organizational Approach to Selecting and Tailoring Implementation Strategies (COAST-IS)","recruitment_status":"Active, not recruiting","last_update_posted":"January 8, 2021"},"NCT02343939":{"publications":["32414848"],"projects":["1U01CA232486-01"],"title":"Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) (ENTO in AML)","recruitment_status":"Terminated","last_update_posted":"November 15, 2019"},"NCT02404220":{"publications":["32414848"],"projects":["1U01CA232486-01"],"title":"Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","recruitment_status":"Terminated","last_update_posted":"January 2, 2020"},"NCT03135028":{"publications":["32414848"],"projects":["1U01CA232486-01"],"title":"Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)","recruitment_status":"Terminated","last_update_posted":"March 6, 2020"},"NCT01141126":{"publications":["32414848"],"projects":["1U01CA232486-01"]},"NCT02828358":{"publications":["32414848"],"projects":["1U01CA232486-01"],"title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","recruitment_status":"Active, not recruiting","last_update_posted":"August 2, 2021"},"NCT03705507":{"publications":["32414848"],"projects":["1U01CA232486-01"],"title":"International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)","recruitment_status":"Recruiting","last_update_posted":"January 19, 2021"},"NCT00557193":{"publications":["32414848"],"projects":["1U01CA232486-01"],"title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","recruitment_status":"Active, not recruiting","last_update_posted":"March 25, 2021"},"NCT04317092":{"publications":["32457999"],"projects":["1U24CA233032-01"],"title":"Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)","recruitment_status":"Active, not recruiting","last_update_posted":"March 3, 2021"},"NCT04315298":{"publications":["32457999"],"projects":["1U24CA233032-01"],"title":"Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","recruitment_status":"Completed","last_update_posted":"October 1, 2020"},"NCT02451423":{"publications":["32497499"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Neoadjuvant Atezolizumab in Localized Bladder Cancer","recruitment_status":"Recruiting","last_update_posted":"March 30, 2020"},"NCT02215967":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"October 8, 2019"},"NCT02658929":{"publications":["32516895","33558511"],"projects":["2P01CA155258-06"],"title":"Study of bb2121 in Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"December 4, 2020"},"NCT03274219":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of bb21217 in Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"March 18, 2021"},"NCT03093168":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma","recruitment_status":"Unknown","last_update_posted":"February 27, 2019"},"NCT03338972":{"publications":["32516895","33914708"],"projects":["2P01CA155258-06","1U01CA247548-01"],"title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"June 10, 2021"},"NCT02546167":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"CART-BCMA Cells for Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"August 4, 2020"},"NCT03661554":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)","recruitment_status":"Unknown","last_update_posted":"September 10, 2018"},"NCT03196414":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"May 2, 2019"},"NCT03455972":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT","recruitment_status":"Recruiting","last_update_posted":"May 19, 2021"},"NCT03716856":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"October 8, 2020"},"NCT03302403":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"October 8, 2020"},"NCT03380039":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"October 12, 2020"},"NCT03430011":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)","recruitment_status":"Active, not recruiting","last_update_posted":"June 1, 2021"},"NCT03090659":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)","recruitment_status":"Active, not recruiting","last_update_posted":"September 2, 2021"},"NCT03548207":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03288493":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT02064387":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916","recruitment_status":"Completed","last_update_posted":"August 11, 2020"},"NCT03525678":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody","recruitment_status":"Active, not recruiting","last_update_posted":"November 23, 2020"},"NCT02514239":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients","recruitment_status":"Completed","last_update_posted":"July 22, 2021"},"NCT03486067":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"August 20, 2021"},"NCT03269136":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma","recruitment_status":"Active, not recruiting","last_update_posted":"July 2, 2021"},"NCT03489525":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT03287908":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Recruiting","last_update_posted":"August 27, 2021"},"NCT04184050":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT03448978":{"publications":["32516895","32632095"],"projects":["2P01CA155258-06"],"title":"Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma","recruitment_status":"Recruiting","last_update_posted":"February 10, 2021"},"NCT03266692":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma","recruitment_status":"Terminated","last_update_posted":"March 30, 2020"},"NCT03651128":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)","recruitment_status":"Recruiting","last_update_posted":"August 11, 2020"},"NCT04181827":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT04126200":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)","recruitment_status":"Recruiting","last_update_posted":"July 20, 2021"},"NCT04246047":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)","recruitment_status":"Active, not recruiting","last_update_posted":"July 22, 2021"},"NCT03502577":{"publications":["32516895","33054076","33914708"],"projects":["2P01CA155258-06","1U01CA247548-01"],"title":"BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"August 2, 2021"},"NCT04093596":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)","recruitment_status":"Recruiting","last_update_posted":"June 24, 2021"},"NCT03940833":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM","recruitment_status":"Recruiting","last_update_posted":"May 7, 2019"},"NCT03848845":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)","recruitment_status":"Active, not recruiting","last_update_posted":"May 20, 2021"},"NCT03544281":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)","recruitment_status":"Recruiting","last_update_posted":"May 19, 2021"},"NCT03715478":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex","recruitment_status":"Recruiting","last_update_posted":"August 10, 2020"},"NCT04091126":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)","recruitment_status":"Recruiting","last_update_posted":"July 20, 2021"},"NCT04196491":{"publications":["32516895"],"projects":["2P01CA155258-06"],"title":"A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)","recruitment_status":"Recruiting","last_update_posted":"May 18, 2021"},"NCT03225105":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"M3541 in Combination With Radiotherapy in Subjects With Solid Tumors","recruitment_status":"Completed","last_update_posted":"September 14, 2020"},"NCT02588105":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)","recruitment_status":"Active, not recruiting","last_update_posted":"August 18, 2021"},"NCT02494583":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","recruitment_status":"Active, not recruiting","last_update_posted":"March 10, 2021"},"NCT03189719":{"publications":["32541866"],"projects":["1U54CA244719-01"],"title":"First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)","recruitment_status":"Active, not recruiting","last_update_posted":"July 6, 2021"},"NCT01120288":{"publications":["32550915"],"projects":["1U01DE029255-01"],"title":"A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases","recruitment_status":"Completed","last_update_posted":"July 5, 2018"},"NCT00466583":{"publications":["32550915"],"projects":["1U01DE029255-01"],"title":"Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma","recruitment_status":"Completed","last_update_posted":"July 7, 2011"},"NCT00400946":{"publications":["32606318"],"projects":["3R00CA181500-04S1"],"title":"Treatment of Acute Lymphoblastic Leukemia in Children","recruitment_status":"Completed","last_update_posted":"November 20, 2019"},"NCT00408005":{"publications":["32606318"],"projects":["3R00CA181500-04S1"],"title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"May 25, 2021"},"NCT01191060":{"publications":["32687451"],"projects":["2P01CA155258-06"],"title":"Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)","recruitment_status":"Completed","last_update_posted":"April 18, 2019"},"NCT03958383":{"publications":["32690669","32849544"],"projects":["1U01CA233102-01","1U54CA232568-01"],"title":"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma","recruitment_status":"Recruiting","last_update_posted":"November 27, 2020"},"NCT01415882":{"publications":["32724061"],"projects":["1U54CA224018-01"],"title":"Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","recruitment_status":"Recruiting","last_update_posted":"April 8, 2021"},"NCT04358276":{"publications":["32746799"],"projects":["1R01CA249460-01"],"title":"Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study","recruitment_status":"Recruiting","last_update_posted":"February 16, 2021"},"NCT03278340":{"publications":["32942054"],"projects":["1R01CA210259-01A1"],"title":"Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)","recruitment_status":"Enrolling by invitation","last_update_posted":"July 9, 2021"},"NCT02181413":{"publications":["32945549"],"projects":["1U01CA244291-01"],"title":"A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant","recruitment_status":"Active, not recruiting","last_update_posted":"March 9, 2021"},"NCT00114101":{"publications":["32945549"],"projects":["1U01CA244291-01"],"title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","recruitment_status":"Active, not recruiting","last_update_posted":"June 23, 2021"},"NCT02550327":{"publications":["32961746","34025067"],"projects":["1U54CA224083-01"],"title":"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"June 22, 2021"},"NCT01560923":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer","recruitment_status":"Completed","last_update_posted":"April 3, 2020"},"NCT02073123":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma","recruitment_status":"Completed","last_update_posted":"June 5, 2020"},"NCT02835729":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia","recruitment_status":"Completed","last_update_posted":"June 4, 2020"},"NCT02052648":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors","recruitment_status":"Completed","last_update_posted":"May 28, 2020"},"NCT03301636":{"publications":["33005623"],"projects":["1U01CA224151-01"],"title":"A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)","recruitment_status":"Terminated","last_update_posted":"June 5, 2020"},"NCT02502648":{"publications":["33005623"],"projects":["1U01CA224151-01"]},"NCT02728102":{"publications":["33054076"],"projects":["2P01CA155258-06"],"title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","recruitment_status":"Active, not recruiting","last_update_posted":"September 9, 2021"},"NCT04514341":{"publications":["33121536"],"projects":["1UG3CA233229-01"],"title":"Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up","recruitment_status":"Not yet recruiting","last_update_posted":"August 14, 2020"},"NCT02840058":{"publications":["33188038"],"projects":["2UM1CA154967-07"],"title":"Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)","recruitment_status":"Recruiting","last_update_posted":"August 2, 2021"},"NCT04302675":{"publications":["33203635"],"projects":["1P50CA244688-01"],"title":"Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)","recruitment_status":"Active, not recruiting","last_update_posted":"July 26, 2021"},"NCT03224507":{"publications":["33255368"],"projects":["2P01CA155258-06"],"title":"Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)","recruitment_status":"Recruiting","last_update_posted":"April 21, 2020"},"NCT04071457":{"publications":["33255368"],"projects":["2P01CA155258-06"],"title":"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)","recruitment_status":"Recruiting","last_update_posted":"February 24, 2021"},"NCT04513639":{"publications":["33255368"],"projects":["2P01CA155258-06"],"title":"The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study","recruitment_status":"Recruiting","last_update_posted":"June 18, 2021"},"NCT03683277":{"publications":["33255368"],"projects":["2P01CA155258-06"],"title":"IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)","recruitment_status":"Not yet recruiting","last_update_posted":"September 25, 2018"},"NCT03077477":{"publications":["33328226"],"projects":["1U01CA232488-01"],"title":"Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"June 14, 2018"},"NCT02369874":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)","recruitment_status":"Completed","last_update_posted":"February 10, 2021"},"NCT00404339":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 18, 2016"},"NCT00257738":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Completed","last_update_posted":"October 17, 2019"},"NCT02426892":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"February 17, 2020"},"NCT01147991":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer","recruitment_status":"Completed","last_update_posted":"February 28, 2012"},"NCT03821272":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients","recruitment_status":"Recruiting","last_update_posted":"May 13, 2021"},"NCT02002182":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"July 2, 2021"},"NCT02865135":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 9, 2021"},"NCT03260023":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","recruitment_status":"Recruiting","last_update_posted":"June 29, 2021"},"NCT03418480":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"HPV Anti-CD40 RNA Vaccine (HARE-40)","recruitment_status":"Active, not recruiting","last_update_posted":"May 6, 2021"},"NCT04369937":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for &quot;Intermediate Risk&quot; HPV-16-associated Head and Neck Squamous Cell Carcinoma","recruitment_status":"Recruiting","last_update_posted":"October 22, 2020"},"NCT02544880":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC","recruitment_status":"Completed","last_update_posted":"June 15, 2021"},"NCT04247282":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection","recruitment_status":"Suspended\n                  \n      <!--","last_update_posted":"June 9, 2021"},"NCT02999646":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC","recruitment_status":"Recruiting","last_update_posted":"March 30, 2021"},"NCT03568058":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","recruitment_status":"Active, not recruiting","last_update_posted":"December 9, 2020"},"NCT04266730":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)","recruitment_status":"Not yet recruiting","last_update_posted":"July 8, 2021"},"NCT03689192":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"February 12, 2020"},"NCT00019110":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer","recruitment_status":"Completed","last_update_posted":"April 29, 2015"},"NCT00019331":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors","recruitment_status":"Completed","last_update_posted":"June 20, 2013"},"NCT00021424":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 30, 2015"},"NCT00027534":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer","recruitment_status":"Completed","last_update_posted":"September 8, 2014"},"NCT01462838":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Immune Therapy of HPV-induced Cancers","recruitment_status":"Completed","last_update_posted":"June 23, 2015"},"NCT01998542":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)","recruitment_status":"Completed","last_update_posted":"January 23, 2020"},"NCT02163057":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma","recruitment_status":"Completed","last_update_posted":"January 22, 2021"},"NCT02291055":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"February 19, 2020"},"NCT02526316":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)","recruitment_status":"Completed","last_update_posted":"July 2, 2017"},"NCT03162224":{"publications":["33368875"],"projects":["1U01DE029188-01"],"title":"Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer","recruitment_status":"Completed","last_update_posted":"April 27, 2021"},"NCT03701295":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement","recruitment_status":"Completed","last_update_posted":"September 9, 2021"},"NCT03724084":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT04065399":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)","recruitment_status":"Recruiting","last_update_posted":"May 6, 2021"},"NCT04067336":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia","recruitment_status":"Recruiting","last_update_posted":"August 24, 2021"},"NCT02698176":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)","recruitment_status":"Terminated","last_update_posted":"January 27, 2021"},"NCT03068351":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"February 7, 2020"},"NCT03292172":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer","recruitment_status":"Terminated","last_update_posted":"November 6, 2020"},"NCT03255096":{"publications":["33371192"],"projects":["5R01CA176745-09"],"title":"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6","recruitment_status":"Completed","last_update_posted":"January 28, 2021"},"NCT04320238":{"publications":["33402434"],"projects":["1U01CA224348-01"],"title":"Experimental Trial of rhIFN&#945; Nasal Drops to Prevent 2019-nCOV in Medical Staff","recruitment_status":"Recruiting","last_update_posted":"March 31, 2020"},"NCT03019003":{"publications":["33403469"],"projects":["1U01DE029188-01"],"title":"Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients","recruitment_status":"Recruiting","last_update_posted":"December 1, 2020"},"NCT03525795":{"publications":["33403469"],"projects":["1U01DE029188-01"],"title":"ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors","recruitment_status":"Completed","last_update_posted":"January 11, 2021"},"NCT03854474":{"publications":["33403469"],"projects":["1U01DE029188-01"],"title":"Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT01693562":{"publications":["33420629"],"projects":["1U01CA233100-01"],"title":"A Phase 1/2 Study to Evaluate MEDI4736","recruitment_status":"Completed","last_update_posted":"May 13, 2021"},"NCT03125239":{"publications":["33527899"],"projects":["3R01CA204396-02S1"],"title":"Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia","recruitment_status":"Completed","last_update_posted":"June 30, 2020"},"NCT01495598":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","recruitment_status":"Active, not recruiting","last_update_posted":"September 5, 2021"},"NCT02659930":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma","recruitment_status":"Recruiting","last_update_posted":"September 5, 2021"},"NCT00006518":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT00092222":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT01419561":{"publications":["33608378"],"projects":["2UM1CA154967-07"],"title":"History of the KSHV Inflammatory Cytokine Syndrome (KICS)","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT00983424":{"publications":["33626321"],"projects":["3U54CA224065-01S1"],"title":"Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer","recruitment_status":"Completed","last_update_posted":"September 16, 2013"},"NCT02188264":{"publications":["33626321"],"projects":["3U54CA224065-01S1"],"title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"April 2, 2021"},"NCT00003950":{"publications":["33626321"],"projects":["3U54CA224065-01S1"],"title":"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer","recruitment_status":"Completed","last_update_posted":"March 7, 2014"},"NCT01391143":{"publications":["33658518"],"projects":["1U54CA224079-01"],"title":"Safety Study of MGA271 in Refractory Cancer","recruitment_status":"Completed","last_update_posted":"January 10, 2020"},"NCT04129320":{"publications":["33658518"],"projects":["1U54CA224079-01"],"title":"Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"October 14, 2020"},"NCT01942837":{"publications":["33664492"],"projects":["1U01CA233100-01"],"title":"Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling","recruitment_status":"Active, not recruiting","last_update_posted":"January 12, 2021"},"NCT01924689":{"publications":["33669386"],"projects":["1UG3CA244687-01"],"title":"Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies","recruitment_status":"Completed","last_update_posted":"September 9, 2019"},"NCT02807805":{"publications":["33737681"],"projects":["1U54CA233306-01"],"title":"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 19, 2021"},"NCT03111992":{"publications":["33777050"],"projects":["1U01CA244291-01"],"title":"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma","recruitment_status":"Completed","last_update_posted":"September 9, 2020"},"NCT02703623":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"November 12, 2020"},"NCT01688492":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 10, 2021"},"NCT04388852":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers","recruitment_status":"Recruiting","last_update_posted":"June 29, 2021"},"NCT02787005":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)","recruitment_status":"Active, not recruiting","last_update_posted":"August 23, 2021"},"NCT03834493":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT02312557":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide","recruitment_status":"Active, not recruiting","last_update_posted":"May 17, 2021"},"NCT03770455":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC","recruitment_status":"Active, not recruiting","last_update_posted":"October 19, 2020"},"NCT03338790":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)","recruitment_status":"Active, not recruiting","last_update_posted":"August 30, 2021"},"NCT02861573":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03658447":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)","recruitment_status":"Active, not recruiting","last_update_posted":"December 23, 2020"},"NCT03093428":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC","recruitment_status":"Active, not recruiting","last_update_posted":"July 28, 2021"},"NCT03834506":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)","recruitment_status":"Active, not recruiting","last_update_posted":"June 9, 2021"},"NCT03248570":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects","recruitment_status":"Recruiting","last_update_posted":"May 26, 2021"},"NCT02998567":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)","recruitment_status":"Active, not recruiting","last_update_posted":"November 17, 2020"},"NCT03582475":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","recruitment_status":"Recruiting","last_update_posted":"July 14, 2021"},"NCT03572478":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer","recruitment_status":"Terminated","last_update_posted":"March 9, 2021"},"NCT03834519":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT02484404":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers","recruitment_status":"Recruiting","last_update_posted":"September 13, 2021"},"NCT03330405":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors","recruitment_status":"Active, not recruiting","last_update_posted":"September 8, 2021"},"NCT04446117":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT03849469":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)","recruitment_status":"Recruiting","last_update_posted":"August 18, 2021"},"NCT03406858":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 1, 2021"},"NCT03217747":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","recruitment_status":"Recruiting","last_update_posted":"October 30, 2020"},"NCT03821246":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy","recruitment_status":"Recruiting","last_update_posted":"November 12, 2020"},"NCT03473925":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)","recruitment_status":"Completed","last_update_posted":"July 2, 2021"},"NCT04020094":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)","recruitment_status":"Withdrawn\n                  \n      <!--","last_update_posted":"July 21, 2021"},"NCT03835533":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)","recruitment_status":"Recruiting","last_update_posted":"August 3, 2021"},"NCT04090775":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma","recruitment_status":"Recruiting","last_update_posted":"October 11, 2019"},"NCT03518606":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)","recruitment_status":"Active, not recruiting","last_update_posted":"September 16, 2021"},"NCT03532217":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"September 17, 2021"},"NCT03204812":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Completed","last_update_posted":"April 15, 2021"},"NCT02985957":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)","recruitment_status":"Recruiting","last_update_posted":"April 23, 2021"},"NCT03879122":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 12, 2020"},"NCT03866382":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03454451":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","recruitment_status":"Recruiting","last_update_posted":"July 27, 2021"},"NCT02655822":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers","recruitment_status":"Completed","last_update_posted":"August 30, 2021"},"NCT04089553":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"August 3, 2021"},"NCT02740985":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","recruitment_status":"Active, not recruiting","last_update_posted":"July 30, 2021"},"NCT04381832":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)","recruitment_status":"Recruiting","last_update_posted":"July 28, 2021"},"NCT03792841":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC","recruitment_status":"Recruiting","last_update_posted":"June 7, 2021"},"NCT04631601":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","recruitment_status":"Recruiting","last_update_posted":"August 23, 2021"},"NCT03972657":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"July 12, 2021"},"NCT04702737":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT04221542":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 2, 2021"},"NCT03577028":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Study of HPN424 in Patients With Advanced Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"October 5, 2020"},"NCT04397276":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT03089203":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"January 14, 2021"},"NCT03873805":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"March 10, 2021"},"NCT03753243":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 23, 2020"},"NCT03810105":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of Olaparib and Durvalumab in Prostate Cancer","recruitment_status":"Recruiting","last_update_posted":"September 16, 2021"},"NCT03016312":{"publications":["33820953"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)","recruitment_status":"Active, not recruiting","last_update_posted":"August 19, 2021"},"NCT04131413":{"publications":["33842408"],"projects":["1U01CA233056-01","1U01CA233097-01"],"title":"HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia","recruitment_status":"Recruiting","last_update_posted":"July 6, 2021"},"NCT01440088":{"publications":["33859749"],"projects":["3R01CA187532-03S1"],"title":"A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma","recruitment_status":"Completed","last_update_posted":"June 2, 2016"},"NCT01746979":{"publications":["33859749"],"projects":["3R01CA187532-03S1"],"title":"Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)","recruitment_status":"Completed","last_update_posted":"December 2, 2017"},"NCT03747484":{"publications":["33879601"],"projects":["2UM1CA154967-07"],"title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","recruitment_status":"Recruiting","last_update_posted":"July 8, 2021"},"NCT02014909":{"publications":["33888713"],"projects":["1U01DE028227-01"],"title":"A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors","recruitment_status":"Completed","last_update_posted":"July 24, 2017"},"NCT03254927":{"publications":["33888713"],"projects":["1U01DE028227-01"],"title":"A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma","recruitment_status":"Completed","last_update_posted":"April 28, 2021"},"NCT03684889":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"February 10, 2021"},"NCT01865617":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","recruitment_status":"Completed","last_update_posted":"July 20, 2021"},"NCT02706392":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies","recruitment_status":"Recruiting","last_update_posted":"July 8, 2021"},"NCT03103971":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia","recruitment_status":"Recruiting","last_update_posted":"September 10, 2021"},"NCT02706405":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","recruitment_status":"Active, not recruiting","last_update_posted":"July 16, 2021"},"NCT02631044":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","recruitment_status":"Recruiting","last_update_posted":"June 21, 2021"},"NCT03277729":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","recruitment_status":"Recruiting","last_update_posted":"July 13, 2021"},"NCT03105336":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT02614066":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)","recruitment_status":"Active, not recruiting","last_update_posted":"June 28, 2021"},"NCT03331198":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","recruitment_status":"Recruiting","last_update_posted":"May 7, 2021"},"NCT03575351":{"publications":["33914708"],"projects":["1U01CA247548-01"],"title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)","recruitment_status":"Active, not recruiting","last_update_posted":"June 10, 2021"},"NCT02504372":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)","recruitment_status":"Active, not recruiting","last_update_posted":"July 17, 2020"},"NCT02998528":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)","recruitment_status":"Active, not recruiting","last_update_posted":"August 26, 2020"},"NCT04025879":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","recruitment_status":"Recruiting","last_update_posted":"August 25, 2021"},"NCT04214262":{"publications":["33937052"],"projects":["1U01CA233102-01"],"title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","recruitment_status":"Recruiting","last_update_posted":"September 14, 2021"},"NCT02884102":{"publications":["33963182"],"projects":["1U2CCA233303-01"],"title":"MMRF Molecular Profiling Protocol","recruitment_status":"Recruiting","last_update_posted":"March 19, 2019"},"NCT01239134":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)","recruitment_status":"Completed","last_update_posted":"August 14, 2019"},"NCT04021043":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers","recruitment_status":"Recruiting","last_update_posted":"January 14, 2021"},"NCT02740270":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas","recruitment_status":"Completed","last_update_posted":"February 21, 2021"},"NCT02628574":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab","recruitment_status":"Completed","last_update_posted":"October 26, 2020"},"NCT02598960":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.","recruitment_status":"Completed","last_update_posted":"December 21, 2020"},"NCT04225039":{"publications":["33976133"],"projects":["1U01CA224348-01","1U2CCA233262-01"],"title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","recruitment_status":"Recruiting","last_update_posted":"February 5, 2021"},"NCT01804465":{"publications":["33986125"],"projects":["1U01CA233100-01","1U01CA244452-01"],"title":"Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer","recruitment_status":"Completed","last_update_posted":"August 18, 2021"},"NCT01626495":{"publications":["34006631"],"projects":["1U01CA232361-01A1"],"title":"Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)","recruitment_status":"Completed","last_update_posted":"March 23, 2020"},"NCT04427527":{"publications":["34011410"],"projects":["1UG3CA233282-01"],"title":"Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)","recruitment_status":"Recruiting","last_update_posted":"May 3, 2021"},"NCT01383538":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma","recruitment_status":"Completed","last_update_posted":"August 8, 2017"},"NCT01195415":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"August 7, 2017"},"NCT01064622":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"August 14, 2015"},"NCT01088815":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas","recruitment_status":"Completed","last_update_posted":"April 26, 2019"},"NCT01487785":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients","recruitment_status":"Completed","last_update_posted":"December 19, 2020"},"NCT02358161":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)","recruitment_status":"Completed","last_update_posted":"January 9, 2020"},"NCT01373164":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"May 16, 2018"},"NCT03941093":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"September 17, 2021"},"NCT04054362":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PINBALL)","recruitment_status":"Unknown","last_update_posted":"December 16, 2019"},"NCT04524702":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer","recruitment_status":"Recruiting","last_update_posted":"February 21, 2021"},"NCT03883919":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy","recruitment_status":"Active, not recruiting","last_update_posted":"May 18, 2021"},"NCT03331562":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A SU2C Catalyst&#174; Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer","recruitment_status":"Completed","last_update_posted":"October 8, 2020"},"NCT03307148":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)","recruitment_status":"Completed","last_update_posted":"January 22, 2020"},"NCT02715804":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma","recruitment_status":"Terminated","last_update_posted":"July 14, 2020"},"NCT01959139":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer","recruitment_status":"Active, not recruiting","last_update_posted":"January 5, 2021"},"NCT01472198":{"publications":["34025067"],"projects":["1U54CA224083-01"],"title":"A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma","recruitment_status":"Completed","last_update_posted":"March 10, 2015"},"NCT03985852":{"publications":["34078380"],"projects":["1U01CA232826-01"],"title":"Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE)","recruitment_status":"Enrolling by invitation","last_update_posted":"August 27, 2021"},"NCT02588443":{"publications":["34101617"],"projects":["1U01CA224193-01"],"title":"Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma","recruitment_status":"Completed","last_update_posted":"April 16, 2019"},"NCT02453594":{"publications":["34113750"],"projects":["1U54CA232568-01"],"title":"Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)","recruitment_status":"Active, not recruiting","last_update_posted":"April 19, 2021"},"NCT02992964":{"publications":["34113750"],"projects":["1U54CA232568-01"],"title":"Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers","recruitment_status":"Active, not recruiting","last_update_posted":"February 15, 2021"},"NCT03241940":{"publications":["34113750"],"projects":["1U54CA232568-01"],"title":"Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"August 17, 2021"},"NCT03289455":{"publications":["34113750"],"projects":["1U54CA232568-01"],"title":"CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)","recruitment_status":"Completed","last_update_posted":"February 1, 2021"},"NCT04365257":{"publications":["34114951"],"projects":["1U01CA247576-01"],"title":"Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)","recruitment_status":"Recruiting","last_update_posted":"June 9, 2021"},"NCT02306954":{"publications":["34172518"],"projects":["1U54CA232568-01"],"title":"Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer","recruitment_status":"Recruiting","last_update_posted":"March 3, 2020"},"NCT03607617":{"publications":["34174834"],"projects":["1P50CA244289-01"],"title":"ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action (ASCEND)","recruitment_status":"Active, not recruiting","last_update_posted":"June 15, 2021"},"NCT00546156":{"publications":["34188163"],"projects":["1U01CA224348-01"],"title":"Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer","recruitment_status":"Completed","last_update_posted":"May 18, 2021"},"NCT02484443":{"publications":["34244307"],"projects":["1U54CA232561-01A1"],"title":"Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma","recruitment_status":"Active, not recruiting","last_update_posted":"August 5, 2021"},"NCT03233854":{"publications":["34312556"],"projects":["1U54CA232568-01"],"title":"CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"August 17, 2021"},"NCT04088890":{"publications":["34312556"],"projects":["1U54CA232568-01"],"title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","recruitment_status":"Recruiting","last_update_posted":"August 3, 2021"},"NCT04131062":{"title":"Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants","recruitment_status":"","last_update_posted":"January 22, 2021","publications":[],"projects":["1R01CA211723-01A1"]},"NCT03698162":{"title":"Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases","recruitment_status":"","last_update_posted":"April 5, 2021","publications":[],"projects":["1R33CA225400-01"]},"NCT01946789":{"title":"A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors","recruitment_status":"","last_update_posted":"April 17, 2019","publications":[],"projects":["2UM1CA154967-07"]},"NCT01961115":{"title":"Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma","recruitment_status":"Completed","last_update_posted":"June 8, 2018","publications":[],"projects":["2UM1CA154967-07"]},"NCT04751383":{"title":"Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma","recruitment_status":"","last_update_posted":"August 30, 2021","publications":[],"projects":["2UM1CA154967-07"]},"NCT04500548":{"title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","recruitment_status":"","last_update_posted":"August 26, 2021","publications":[],"projects":["2UM1CA154967-07"]},"NCT03513952":{"title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","recruitment_status":"","last_update_posted":"September 14, 2021","publications":[],"projects":["2UM1CA154967-07"]},"NCT02243579":{"title":"Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome","recruitment_status":"Completed","last_update_posted":"September 20, 2019","publications":[],"projects":["2UM1CA154967-07"]},"NCT04410302":{"title":"Patient-Derived Xenografts to Reduce Cancer Health Disparities","recruitment_status":"","last_update_posted":"July 13, 2021","publications":[],"projects":["1U54CA233306-01"]},"NCT04406714":{"title":"Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)","recruitment_status":"","last_update_posted":"May 12, 2021","publications":[],"projects":["1UG3CA233251-01"]},"NCT03892967":{"title":"Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial","recruitment_status":"","last_update_posted":"August 13, 2021","publications":[],"projects":["1UM1CA233033-01"]},"NCT03988543":{"title":"Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center","recruitment_status":"","last_update_posted":"March 3, 2021","publications":[],"projects":["1UM1CA233035-01"]},"NCT03850912":{"title":"Symptom Management Implementation of Patient Reported Outcomes in Oncology","recruitment_status":"","last_update_posted":"September 16, 2020","publications":[],"projects":["1UM1CA233080-01"]},"NCT04199026":{"title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","recruitment_status":"","last_update_posted":"March 6, 2020","publications":[],"projects":["3R01CA180279-05S1"]},"NCT03538938":{"title":"Improving Quitline Support Study","recruitment_status":"","last_update_posted":"May 17, 2021","publications":[],"projects":["5R01CA218156-02"]},"NCT04314284":{"title":"Patient-Centered Intervention to Reduce Cancer Patients&apos; Financial Toxicity","recruitment_status":"","last_update_posted":"January 14, 2021","publications":[],"projects":["1P50CA244431-01"]},"NCT04585919":{"title":"Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening","recruitment_status":"","last_update_posted":"April 1, 2021","publications":[],"projects":["1P50CA244433-01"]},"NCT05021133":{"title":"Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)","recruitment_status":"Not yet recruiting","last_update_posted":"August 31, 2021","publications":[],"projects":["1P50CA244693-01"]},"NCT04337203":{"title":"Shared Healthcare Actions and Reflections Electronic Systems in Survivorship","recruitment_status":"","last_update_posted":"June 18, 2021","publications":[],"projects":["1P50CA244693-01"]},"NCT04746794":{"title":"Early Detection of GEnetic Risk (EDGE)","recruitment_status":"","last_update_posted":"February 10, 2021","publications":[],"projects":["1U01CA232795-01A1"]},"NCT04323774":{"title":"Intervention For AYAS With Cancer Risk Syndromes","recruitment_status":"","last_update_posted":"April 13, 2021","publications":[],"projects":["1U01CA243688-01"]},"NCT04939597":{"title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","recruitment_status":"","last_update_posted":"June 25, 2021","publications":[],"projects":["1U01CA246568-01"]},"NCT04789720":{"title":"Using Information Technology to Improve Outcomes for Children Living With Cancer","recruitment_status":"","last_update_posted":"June 18, 2021","publications":[],"projects":["1U01CA246612-01"]},"NCT04089358":{"title":"Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study","recruitment_status":"","last_update_posted":"August 25, 2021","publications":[],"projects":["1U01CA246665-01"]},"NCT04941300":{"title":"ColoRectal Cancer Screening for Southern California Community Health Centers","recruitment_status":"","last_update_posted":"July 19, 2021","publications":[],"projects":["1UG3CA233314-01A1"]},"NCT04890054":{"title":"Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC","recruitment_status":"","last_update_posted":"July 15, 2021","publications":[],"projects":["1UG3CA244298-01"]},"NCT04745754":{"title":"The Engaging Primary Care in Cancer Survivorship (EPICS) Study","recruitment_status":"","last_update_posted":"August 4, 2021","publications":[],"projects":["1R01CA249419-01"]},"NCT05006482":{"title":"Geriatric Evaluation and Management With Survivorship Health Education (GEMS) for Older Survivors of Cancer","recruitment_status":"","last_update_posted":"August 31, 2021","publications":[],"projects":["1R01CA249467-01"]},"NCT04428905":{"title":"Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer","recruitment_status":"","last_update_posted":"February 16, 2021","publications":[],"projects":["1R01CA249501-01"]},"NCT04494945":{"title":"Identifying and Caring for Individuals With Inherited Cancer Syndrome","recruitment_status":"","last_update_posted":"June 2, 2021","publications":[],"projects":["1U01CA232819-01A1"]}}